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Available online 18 May 2018Objective: Clinical trials investigating breast cancer treatment often exclude or misrepresent older adults. This
study compares treatment patterns and survival of older women diagnosed with breast cancer between a
Dutch and a British observational cohort.
Materials and Methods:Women aged 70 years and older diagnosed with breast cancer after 1990 with a T0-T2
tumor stage and no evidence of metastatic disease were included from a population-based cohort in the
Netherlands and a British hospital-based cohort in Nottingham. Main outcomes were proportions of local and
systemic treatment, ten-year overall survival and ten-year relative survival for each cohort.
Results: 1439 patients from Nottingham and 2180 patients from the Netherlands were included. Median follow-
up was 12.4 years (IQR 11.0–14.0) in the FOCUS cohort and 6.4 years (IQR 6.2–6.8) in the Nottingham cohort.
British patients were more likely to receive primary endocrine therapy (50.0% vs 7.5%, P b 0.001), and less likely
to be managed with mastectomy or breast-conserving surgery (47.8% vs 90.5%, P b 0.001). Ten-years overall
survival was 39.4% (95% CI 37.4–41.6%) in the FOCUS cohort and 34.3% (95% CI 30.7–38.3) in the Nottingham
cohort (adjusted HR 0.97, 95% CI 0.87–1.08, P = 0.559). Ten-year relative survival was 82.5% (95% CI 75.6–
90.1) in the FOCUS cohort and 77.6% (95% CI 66.4–90.7) in the Nottingham cohort (adjusted relative excess
risk 1.67, 95% CI 1.21–2.29, P = 0.002).
Conclusion: Patients in the Nottingham cohort were more likely to receive primary endocrine therapy and had
worse relative survival compared to the Dutch cohort. These ﬁndings encourage further research to equalize sur-
vival rates of breast cancer throughout Europe.den Univ
).
. This is©2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Evidence shows a rapidly growing group of older patients being
diagnosed with cancer. For breast cancer the median age at diagnosis is
currently 61 years, with 30% of patients above the age of 70 [1]. Clinical
trials exploring treatment options offer little data to guide treatment of
older patients [2]. This appears to be a result of the exclusion or under-
representation of older patients in clinical trials; merely 4% of currently
ongoing trials regarding breast cancer treatment speciﬁcally aim to
include older patients [3]. Moreover, the external validity of trials thatersity Medical Center,
an open access article underdo include older patients is limited, since older patients that are included
have been shown to have fewer comorbidities, a higher socioeconomic
status, better tumor characteristics and better survival outcomes than
the general older population [4].
As there is little evidence originating from trials for this group of
patients, observational data might provide guidance in the treatment
of an ageing population with breast cancer. Registration and the
follow-up of observational cohorts of patients diagnosed with breast
cancer are widely practiced in European countries [5]. Data from these
registries is readily available and has the beneﬁt of overcomingmisrep-
resentation of patients, as there are no exclusion criteria for these
cohorts. When using the appropriate methodology, this observational
data can provide evidence on the effectiveness of the used treatment
strategies for elder patients by evaluating the survival outcomes of the
patients included [6].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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adjuvant treatment strategies and survival outcomes between a Dutch
(the FOCUS cohort, a large population-based cohort of older patients
with breast cancer) and a British cohort (dedicated Primary Breast
Cancer Clinic for Older Women of the Nottingham Breast Unit) includ-
ing patients aged 70 years and older with early stage breast cancer.
2. Materials and Methods
2.1. Cohorts
Dutch patientswere included from the FOCUS cohort (Female breast
cancer in the elderly; Optimized Clinical guidelines Using clinic-
pathological & molecular data), an observational cohort based on the
National Cancer Registry of the Netherlands, a registry of all Dutch
incident cancer cases [7]. This cohort contains all patients diagnosed
with breast cancer between 1997 and 2004 in the western region of
the Netherlands aged 65 years and older. Charts of these patients have
been reviewed by trained personnel in order to collect data on patient
and tumor characteristics, treatment strategies and survival outcomes.
Vital status was recorded through linkage with the municipal popula-
tion registries.
British patients were included from the dedicated Primary Breast
Cancer Clinic for Older Women, established in the Nottingham Breast
Unit [8]. Patients were aged 70 years and older, had early operable
primary breast cancer and were included between 1973 and 2010.
Paper and computerized records from the Histopathology Department
were reviewed by trained personnel to obtain clinical information
from the date of diagnosis till death or last follow-up.
2.2. Procedures
Patients were included if they were aged 70 years or older, with T-
stage T0, T1 or T2 (tumor ≤ 5 cm across), no evidence of metastatic
disease and diagnosed after 1990. Patients were excluded if date of
birth and/or pathological and clinical T-stage was unknown.
The International Classiﬁcation of Diseases and Related Health
Problems (ICD-10) coding was used to ascertain breast cancer [9]. The
tumor-node-metastasis (TNM) Classiﬁcation of Malignant Tumors for
breast cancer 6th edition was used to deﬁne stage of disease [10]. If
available pathological reports were used to determine T- and N-stage,
if missing, clinical T- and N-stage were used to complete TNM staging.
If data on metastases was unknown for a patient, this patient was
assigned as having no metastases. Morphology was categorised into
ductal, lobular, or mixed/other in accordance with the ICD-O-3
classiﬁcation [11].
2.3. Outcomes
Main outcomes were the proportion of given treatment, ten-year
overall survival and ten-year relative survival for each cohort. The
following deﬁnitions were used: breast surgery as the most extensive
breast surgery procedure listed (no surgery, breast-conserving surgery
(BCS),mastectomy). In patients that received any type of breast surgery
the following subsequent treatments were deﬁned: axillary surgery if
any breast surgery (yes or no), radiotherapy (yes or no), adjuvant
endocrine therapy (yes or no), adjuvant chemotherapy (yes or no).
Primary endocrine therapy was deﬁned as endocrine therapy without
receiving surgery (yes or no). Vital status was deﬁned as alive, dead or
unknown. Follow-up time for vital status was deﬁned as time in days
from diagnosis until death or end of follow-up.
2.4. Statistical Analysis
All analyses were performed in R statistics version 3.3.3 using the
prodlim, survival and relsurv packages. Pearson Χ2 test was used tocompare proportional differences of tumor and treatment characteris-
tics between the cohorts. Kaplan-Meier estimates of overall survival
were calculated for each cohort. Univariate and multivariable Cox
Proportional Hazards models were used to compare overall survival
between the cohorts. The following potential confounders were
considered clinically relevant and added in themodel: year of diagnosis,
tumor stage, tumor grade, morphology and ER status. Ten-year relative
survival for each cohort was estimated using the Pohar-Perme method
[12]. National life tables from The Human Mortality Database were
used to estimate expected survival [13]. To model the effect of
covariates on relative survival an additive hazardmodel was employed.
The effect of covariates on the excess hazard was estimated using the
expectation-maximisation method [14]. Estimates of the covariates
are expressed as relative excess risk of death (RER) and they quantify
the relative cancer related excess mortality between the categories of
the included covariates in the model [15]. The multivariable model
included the confounders as mentioned above.
2.5. Additional Analysis
A sensitivity analysiswas performed to assess the impact of variation
in time periods between the cohorts on treatment and survival out-
comes by only including the years with data available fromboth cohorts
(1997 until 2004). To assess variation over time in local therapy in the
UK, local therapy was calculated in two time periods (1990–1999 and
2000–2010).
2.6. Ethics Approval
For the FOCUS cohort anonymised data was provided from the
Dutch Cancer Registry. Therefore, informed consent from patients or
ethical approval was not required for this study. The Nottingham cohort
as a study was part of an ongoing research program approved by local
research ethics committee.
3. Results
3.1. Patient Outcomes
In total, 3619 patients were included in the analyses (Fig. 1).
Included from the FOCUS cohort were 2180 patients (60.2%), with a
median age of 78.1 years (interquartile range (IQR) 73.6–83.6 years)
and a median follow-up of 12.4 years (IQR 11.0–14.0). The 1439
patients (39.7%) included from the Nottingham cohort had a median
age of 77.9 years (IQR 74.3–82.6 years) and a shorter median follow-
up of 6.4 years (IQR 6.2–6.8) compared to the FOCUS cohort patients.
Patient and tumor characteristics for each cohort are presented in
Table 1. Patients from the FOCUS cohort were more often diagnosed
with a lower T-stage. The Nottingham cohort contains more unknown
data on n-stage and morphology due to a lower percentage of
Nottingham cohort patients undergoing surgery.
3.2. Treatment Outcomes
Proportions of primary treatment strategies are represented in Fig. 2
and Supplementary Table 1. For patients of the Nottingham cohort pri-
mary endocrine therapy (PET)was the predominant primary treatment
(50.0%), followed by breast surgery (47.8%), namely mastectomy
(31.1%) and BCS (16.7%). Patients from the FOCUS cohort were far less
likely to receive PET as a primary treatment (7.5%); predominant
primary treatment in the FOCUS cohort consisted of breast surgery
(90.5%), with 60.4% of patients undergoing mastectomy and 30.1% of
patients undergoing BCS (P b 0.001).
Adjuvant treatment strategies for patients that underwent breast
surgery (mastectomy or BCS) are shown in Fig. 3. Axillary surgery was
more often performed in patients in the FOCUS cohort compared to
Fig. 1. Flowchart of patient inclusion.
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observed for adjuvant chemotherapy (2.4% vs 0.3%, P b 0.001) and
adjuvant radiotherapy (38.2% vs 23.4%, P b 0.001). There is a larger
difference in adjuvant radiotherapy for patients that underwent BCS
(80.5% vs 36.9%, P b 0.001). However, in the Nottingham cohort 25.7%
of data on radiotherapy was unknown. Adjuvant endocrine therapy
was provided more often to patients in the Nottingham cohort (40.2%
vs 52.4%, P b 0.001).Table 1
patient and tumor characteristics per cohort.
FOCUS (NL)
N= 2180
Age in years. Median (IQR) 78 (74–84)
FOCUS (NL)
N= 2180
N %
T-stage
0 160 7.3
T1 1008 46.2
T2 1012 46.4
N-stage
N0 1415 64.9
N1 598 27.4
N2/N3 48 2.2
Unknown 119 5.5
Tumor grade
1 293 13.4
2 655 30.0
3 451 20.7
Unknown 781 35.8
Oestrogen receptor status
Positive 1361 62.4
Negative 336 15.4
Unknown 483 22.2
Morphology
Ductal 1594 73.1
Lobular 190 8.7
Other/unknown 396 18.23.3. Survival Outcomes
As shown in Table 2, 1534 of 2180 patients died during follow-up in
the FOCUS cohort and 668 of 1439 patients died in the Nottingham
cohort. Ten-years overall survival was 39.4% (95% conﬁdence interval
(CI) 37.4–41.6%) in the FOCUS cohort and 34.3% (95% CI 30.7–38.3) in
theNottingham cohort (Fig. 4). In univariate survival analysis, overall sur-
vival was slightly worse for patients of the Nottingham cohort whenNottingham (UK)
N= 1439
P-value
78 (74–83) 0.69
Nottingham (UK)
N= 1439
P-value
N %
b0.001
20 1.4
496 34.5
923 64.1
b0.001
311 21.6
150 10.4
58 4.0
920 63.9
0.02
160 11.1
473 32.9
331 23.0
475 33.0
b0.001
1061 66.9
239 16.6
139 9.7
b0.001
1047 72.8
65 5.2
317 22.0
Fig. 2. Treatment strategies per cohort.
Fig. 3. Adjuvant therapy for patients undergone surgery.
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Table 2
Univariate and multivariable analysis of overall survival.
Number of events/number at risk Univariate Multivariablea
Hazard ratio 95% CI P-value Hazard ratioa 95% CI P-value
FOCUS (NL) 1534/2176 1.00 1.00
Nottingham (UK) 668/1439 1.09 0.99–1.94 0.078 0.97 0.87–1.08 0.559
a Adjusted for the following confounders: age, year of diagnosis, tumor stage, tumor grade, morphology and ER status.
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P = 0.078). When taking into account the possible confounders no
difference was observed (HR 0.97, 95% CI 0.87–1.08, P= 0.559).
Ten-year relative survival analysis for each cohort is presented in
Table 3. Ten-year relative survival was 82.5% (95% CI 75.6–90.1) in the
FOCUS cohort and 77.6% (95% CI 66.4–90.7) in the Nottingham cohort.
The relative excess risk (RER) of death for patients in the Nottingham
cohort compared to patients in the FOCUS cohort was 1.87 (95% CI
1.33–2.62, P b 0.001). A multivariable analysis conﬁrmed a higher risk
of dying due to breast cancer for patients of the Nottingham cohort
(RER 1.67, 95% CI 1.21–2.29, P= 0.002).3.4. Additional Analyses
The sensitivity analysis performed for the period 1997–2004 showed
little differences for the treatment strategies for the Nottingham cohort
for this period compared to treatment strategies over thewhole inclusion
period of this cohort (Supplementary Table 2). PET has consistently been
an often used standard primary treatment over time in the Nottingham
cohort; PET was the primary treatment strategy for 60.1% of patients inFig. 4. Overall survithe period 1990–1999 and 41.7% of patients in 2000–2010 (Supplemen-
tary Fig. 1).
In contrast to the main analysis, overall survival was comparable
between both cohorts for the period 1997–2004 in univariate regres-
sion analysis (HR 1.06, 95% CI 0.95–1.20, P = 0.25, Supplementary
Table 3). Consistent with the main analysis no signiﬁcant difference
was found in overall survival between the two cohorts for the period
1997–2004 in multivariable regression analysis (HR 1.05, 95% CI
0.94–1.18, P = 0.39, Supplementary Table 3). Relative survival
analysis of this period showed a relative ten-year survival of 72.6%
(95% CI 57.9–91.1) for the Nottingham cohort, which is slightly
lower compared to the ten-year survival found over the whole
inclusion period. Consequently, excess risk of death (RER) was higher
compared to the ﬁndings from the main analysis between the cohorts
(univariate RER 2.28, 95% CI 1.68–3.10, P b 0.001; multivariable RER
2.04, 95% CI 1.52–2.75, P b 0.001, Supplementary Table 4).
4. Discussion
In this study, we observed signiﬁcant differences between the
FOCUS cohort and the Nottingham cohort in treatment and relativeval per cohort.
Table 3
Univariate and multivariable analysis of relative survival.
Relative survival ten year after diagnosis (95% CI) Univariate Multivariablea
RER 95% CI P-value RERa 95% CI P-value
FOCUS (NL) 82.5 (75.6–90.1) 1.00 1.00
Nottingham (UK) 77.6 (66.4–90.7) 1.87 1.33–2.62 b0.001 1.66 1.21–2.29 0.002
a Adjusted for the following confounders: age, year of diagnosis, tumor stage, tumor grade, morphology and ER status.
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stage breast cancer. The study shows that patients included in the
FOCUS cohort were more likely to be diagnosed with a T0 or T1
stage than their Nottingham counterparts. We observed substantial
variation in primary treatment strategies between the two regions:
PET was far more likely to be received by patients included in the
Nottingham cohort, while breast surgery was preferred primary treat-
ment option for patients of the FOCUS cohort. Ten-year overall
survival was similar between cohorts after adjustment for potential
confounders. Ten-year relative survival was signiﬁcantly lower in
Nottingham patients compared to FOCUS patients, even after adjust-
ment for the confounders.
Variation in tumor size at time of diagnosis could possibly be
explained by variation in population-based screening practices between
theNetherlands and theUK, speciﬁcally England. Theupper age limit for
participation in the NHS Breast Screening Programme was 64 until the
screening policy changed in 2001, with the age limit extending to
includewomen aged 65–70. In theNetherlands screeningwas provided
till the age of 69 until 1998, when the upper age limit was extended to
75 years [16]. Variation in tumor size could also be caused by patient
delay due to variation in breast cancer awareness between the two
countries.
PET was the predominant primary treatment option in the Notting-
ham cohort and was used for a far smaller proportion of patients in the
FOCUS cohort. This ﬁnding corresponds to the results found in previous
studies including smaller cohort studies, cancer registry ﬁndings and a
UK breast surgeon survey on treatment of older patients [17–20].
Growing evidence suggest poor locoregional control with PET: systemic
literature review of randomised controlled trials and non-randomised
studies has shown beneﬁts for surgery over PET in treatment of older
patients in improving disease control and a probable survival beneﬁt
in patients with a life expectancy of ﬁve years or more [21,22]. It is
therefore that the International Society of Geriatric Oncology (SIOG)
and the European Society of Breast Cancer Specialists (EUSOMA) only
recommend PET for patients with a life expectancy of b2 years, or
those patients considered unﬁt for surgery or refuse surgery [2]. It is
questionable whether this was the case for all patients receiving PET
in these cohorts. The wide use of PET in the Nottingham cohort was
mostly historical given the availability of evidence at the time – in fact
Nottingham was the centre of two historical randomised controlled
trials comparing PET with surgery, out of a total of seven such trials
conducted at the time, as reported in a Cochrane review [23–25].
From2000,with the introduction of a combined surgical/oncology clinic
for assessment taking into account of biology, frailty and patient choice,
41.7%of thepatients received PET as opposed to 60.1% in the1990–1999
period (Supplementary Fig. 1).
Further differences were observed in adjuvant treatment strategies,
but that could also explain poorer relative survival in the Nottingham
cohort. Axillary surgery and adjuvant radiotherapy were more often
observed in the FOCUS cohort; however these differences were smaller
when only taking into account the same periods of inclusion (Supple-
mentary Table 2). Adjuvant endocrine therapy was used more often in
the Nottingham cohort. The amount of patients receiving adjuvant
chemotherapy was small in both cohorts. The proportion of no
administration of primary treatment whatsoever was similar. For
patients who had undergone surgery, the ratio of BCS and mastectomy
surgery was fairly similar between cohorts.Relative survival was signiﬁcantly worse for patients in the Notting-
ham cohort compared to those in the FOCUS cohort. This is in line with
ﬁndings of the EUROCARE-5 and EURECCA studies, which reported
large variation in survival outcomes between European countries.
They reported a worse relative survival rates in the UK compared to
most other Western European countries, including the Netherlands
[20,26]. One of the explanations named by the EUROCARE-5 study as
an explanation for lower survival rates in the UK is more advanced
stage of disease at diagnosis, as a result of late detection. Indeed, we ob-
served larger tumor-stages in the Nottingham cohort compared to the
FOCUS cohorts, but relative survival was still signiﬁcantly worse for
the Nottingham cohort after adjustment for confounders including
tumor stage. We hypothesize that the differences in relative survival
that were found in our observational cohorts could be related to the
differences we observed in primary treatment. The frequent use of
PET in the Nottingham cohort might have led to worse disease control
in these patients and a higher likelihood of death due to breast cancer.
Overall survival did not differ signiﬁcantly between cohorts over the
complete follow-up, although the survival curves appear to diverge
after six years, with slightly worse overall survival for the Nottingham
cohort (Fig. 4).
Aside from treatment strategy, other explanations for the difference
in relative survival should be considered. Suboptimal access to
healthcare was named in the EUROCARE-5 study as a possible cause of
lower relative survival. General health of a country's populations has
also been described as an inﬂuence on cancer survival [27]. If patients
are unﬁt to undergo surgery, radiotherapy or chemotherapy because of
comorbidities unrelated to cancer, cancer survival might be affected. Ad-
ditionally, socio-economic status has been shown to have a correlation
with cancer survival [28]. Unfortunately, comorbidities and information
on socio-economic statuswere not available for patients of these cohorts
and could not be compared. Differences in these characteristics might
partly explain the choices for different primary treatment strategies
between cohorts.
Further limitations of our data include the differences between the
populations of our cohorts: the time period for inclusion was broader
in the Nottingham cohort. However, sensitivity analyses did not alter
the main ﬁndings. Furthermore, the data was not complete. Both
cohorts had several incomplete tumor and treatment characteristics,
speciﬁcally the Nottingham cohort had more unknown data on radio-
therapy and tumor characteristics due to less histology being performed
as a results of a smaller share of patients undergoing surgery. Addition-
ally, the Nottingham cohort is a hospital based registry and this gives
way to possible selection bias. It has not been established to what
extend the patients who reach this hospital are representative of the
general population. Selection bias did not occur in the FOCUS cohort,
because it included all consecutive cases of breast cancer in a well-
deﬁned region.
In conclusion, this study showed signiﬁcant differences in treatment
strategies, with a higher proportion of patients receiving primary endo-
crine therapy in a dedicated breast cancer clinic in Nottingham (United
Kingdom) compared to western region of the Netherlands. Among
many other factors that might inﬂuence survival, this might be ex-
plained by the higher use of primary endocrine therapy in Nottingham.
This study should be seen as an addition to existing literature suggesting
primary endocrine therapy is a viable treatment option for a small
group of patients with poor life expectancy and it encourages further
641H. Schuil et al. / Journal of Geriatric Oncology 9 (2018) 635–641research to continue equalizing survival rates of breast cancer through-
out Europe.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jgo.2018.05.004.
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